美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Corgi All World 2x Daily ETF

24.17

0.0000

成交量：6

成交額：146.31

市值：60.43萬

市盈率：- -

高：24.17

開：24.17

低：24.17

收：24.17

52周最高：25.58

52周最低：20.48

股本：2.50萬

流通股本：2.50萬

量比：0.06

換手率：0.02%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

【券商聚焦】中泰國際：多家藥企將公布重要數據推薦創新藥與CXO龍頭

小摩：不太擔心利率上升影響中國醫療健康行業繼續看好生物科技及CXO

創新藥出海之後，CXO能否接住訂單復甦？

科創板收評：權重股拖累科創50指數下行創新藥械、CXO板塊逆勢爆發

东方财富网

盈利修復疊加出海提速，創新藥與CXO投資機遇受關注

CXO概念活躍華神科技漲停

藥企為何愛外包？

港股醫藥實力抗跌！CXO再扛旗，核心ETF（159137）逆市收紅，金斯瑞創5年新高！兩個問題引發關注……

招商基金李佳存：看好CXO板塊beta機會及創新藥優質個股估值修復行情

醫藥外包概念盤初走高昭衍新藥（06127）漲6.14% 機構指CXO為醫藥行業中最亮眼板塊之一

CXO板塊上揚昭衍新藥（06127）漲5.64%、金斯瑞生物科技（01548）漲4.78%

港股異動 | CRO概念股漲幅居前 AIDD利好催化密集 CXO板塊景氣度明確上行

生物製品及CXO行業集體與投資者互動企業「出海」進階從產品輸出邁向能力輸出

ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比

中信建投：內外需改善逐步傳導訂單與業績 CXO有望進入新一輪增長階段

【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升

東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點

分拆上市成利好？金斯瑞大反攻，飆升逾12%！華寶基金港股通醫療ETF（159137）標的指數漲近2%，CXO全線提振

昊海生科：關於參加科創板2026年半年度生物製品及CXO行業集體業績説明會的公告

证券日报网

創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/WX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"WX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":24.1735,"timestamp":1791555254596,"preClose":24.1735,"halted":0,"volume":6,"delay":0,"changeRate":0,"floatShares":25000,"shares":25000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"10-09 13:12:53 EDT","open":24.1735,"high":24.1735,"low":24.1735,"amount":146.305002,"amplitude":0,"askPrice":24.48,"askSize":300,"bidPrice":24.41,"bidSize":300,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":24.1735,"nav":24.45,"aum":611250,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.4711,"preClose":24.1735,"latestTime":"16:30 EDT","volume":10,"amount":240.441,"timestamp":1791491400543,"change":0.2976,"changeRate":0.012311,"amplitude":0},"volumeRatio":0.057719},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","floatShares":25000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.057719,"shares":25000,"dividePrice":0,"high":24.1735,"amplitude":0,"preClose":24.1735,"low":24.1735,"week52Low":20.48,"pbRate":"--","week52High":25.58,"institutionHeld":0,"latestPrice":24.1735,"eps":0,"divideRate":0,"volume":6,"delay":0,"ttmEps":0,"open":24.1735,"prevYearClose":24.72,"prevWeekClose":24.3364,"prevMonthClose":23.9994,"prevQuarterClose":23.9994,"fiveDayClose":24.3364,"twentyDayClose":24.6313,"sixtyDayClose":23.5672},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674892318","title":"【券商聚焦】中泰國際：多家藥企將公布重要數據 推薦創新藥與CXO龍頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674892318?lang=zh_tw&edition=fundamental","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议，LBA是最高级别的研究成果展示，因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中，有四项入选最高级别的主席研讨会。该机构认为，以上情况表明中国创新药研发能力在海外广受认可，因此创新药板块值得继续关注。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WX","01177","09926","LU2097828557.USD","LU0348827113.USD","06160","LU1831875114.USD","LU2488822045.USD","MEDX","LU2399975544.HKD","LU0307460666.USD","LU0314109678.HKD","LU0708995153.HKD","LU1008478684.HKD","06978","159992","LU2125910500.SGD","IBBQ","LU1688375341.USD","02269","06821","LU0823426308.USD","BK1521","LU1960683339.HKD","LU2097828714.EUR","LU0149534421.HKD","LU0327786744.USD","LU0067412154.USD","LU0561508036.HKD","IE00BZ08YR35.GBP","KCE","BK1191","KURE","IE0008369823.USD","IE00B5MMRT66.SGD","LU0029874905.USD","02359","SG9999002463.SGD","00013","LU0320764599.SGD","02268","LU0572944931.SGD","LU0348767384.USD","01093","LU0348783233.USD","LNGR","LU1242518931.SGD","01801","CXO","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673035134","title":"小摩：不太擔心利率上升影響中國醫療健康行業 繼續看好生物科技及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673035134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673035134?lang=zh_tw&edition=fundamental","pubTime":"2026-10-06 11:32","pubTimestamp":1791257520,"startTime":"0","endTime":"0","summary":"另外，该行预期本轮加息周期将于12月再加息一次后结束，而非延续至明年的长期紧缩，因此对利率上升影响中国医疗健康估值并不太担心，并继续看好生物科技及CXO子板块。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EQRR","WX","FNCL","03696","02269","159760","TFNS","VFH","IEIH","LU0976567544.SGD","LU0345769128.USD","159837","IYF","UYG","IE0034235295.USD","GDOC","LU0345769631.USD","LU1974910355.USD","JPMO","XLV","PEX","KBWB","01548","FTXO","SYNB","XBI","TRUF","LU0572944931.SGD","KURE","IYG","LABU","CXO","MEDX","LU1670627923.USD","IXG","IXJ","06990","IE00BKDWB100.SGD","XLF","LU0708995153.HKD","JPO","02359","02268","VHT","LU2168564065.EUR","IBBJ","LNGR","XLBI","HBImain","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672758061","title":"創新藥出海之後，CXO能否接住訂單復甦？","url":"https://stock-news.laohu8.com/highlight/detail?id=2672758061","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672758061?lang=zh_tw&edition=fundamental","pubTime":"2026-10-01 16:18","pubTimestamp":1790842680,"startTime":"0","endTime":"0","summary":"9月医药板块的重估，起点是创新药出海交易的密集落地，真正决定行情能否继续的，却是一个更具体的问题：BD交易能否转化为CXO产业链的订单、收入和利润？公开资料显示，国家药监局9月14日披 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261001/c680429674.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261001/c680429674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["MEDX","BK1574","06978","159992","LNGR","IBBQ","WX","CXO","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671271309","title":"科創板收評：權重股拖累科創50指數下行 創新藥械、CXO板塊逆勢爆發","url":"https://stock-news.laohu8.com/highlight/detail?id=2671271309","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671271309?lang=zh_tw&edition=fundamental","pubTime":"2026-09-30 15:04","pubTimestamp":1790751854,"startTime":"0","endTime":"0","summary":"今日，科创50指数收跌2.58%。盘面上，寒武纪、中芯国际、海光信息、澜起科技等权重股普遍下挫。分行业来看，创新药械、CXO板块逆势爆发，康希诺、泰诺麦博20cm涨停，南模生物涨超19%，近岸蛋白涨超13%，洁特生物涨超12%。半导体板块情绪低迷，芯原股份跌超11%，气派科技、杰华特跌超7%，华峰测控跌超6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202609303887676434.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202609303887676434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["KSTR","WX","159371","CXO","399265"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671725228","title":"盈利修復疊加出海提速，創新藥與CXO投資機遇受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2671725228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671725228?lang=zh_tw&edition=fundamental","pubTime":"2026-09-30 07:14","pubTimestamp":1790723656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","WX","CXO","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670224407","title":"CXO概念活躍 華神科技漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2670224407","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670224407?lang=zh_tw&edition=fundamental","pubTime":"2026-09-28 09:32","pubTimestamp":1790559162,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670098406","title":"藥企為何愛外包？","url":"https://stock-news.laohu8.com/highlight/detail?id=2670098406","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670098406?lang=zh_tw&edition=fundamental","pubTime":"2026-09-28 00:54","pubTimestamp":1790528045,"startTime":"0","endTime":"0","summary":"港股聚集了国内一批全球化程度很高的CXO企业，大部分收入来自海外市场，与全球创新药的冷暖密切相关。CXO对整个创新药产业的价值，可以归纳为三点：第一是降本。简言之，药企聚焦药物创新想法，CXO承接落地执行，专业化分工可抬升全球新药研发整体效率。行业数据显示，约七八成的ADC项目会外包给CDMO企业，远高于其他生物制剂约三成的外包率，临床管线爆发直接带动外包订单快速增长，是CXO当中公认的黄金赛道。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790302671106581161","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["300363","LU0634319403.HKD","LU0348766576.USD","LU0516422366.SGD","603456","LU0516422952.EUR","LU0823426480.USD","LU0307460666.USD","LU0708995153.HKD","LU0856984785.SGD","LU0181495838.USD","LU0516422440.USD","BK1576","IBBQ","06821","02359","LU0128526141.USD","LU0348735423.USD","LU2125910500.SGD","02268","LU1880383366.USD","LNGR","LU0043850808.USD","LU1242518857.USD","LU1046422090.SGD","688238","MEDX","06978","LU0823426308.USD","LU0516423091.SGD","LU0456827905.SGD","LU1688375341.USD","BK0239","KCAI","LU0051755006.USD","LU0052750758.USD","LU0540923850.HKD","LU0348767384.USD","LU0348827113.USD","LU0561508036.HKD","02269","LU2488822045.USD","WX","LU0039217434.USD","LU0588546209.SGD","LU0572944931.SGD","VXUS","LU0029874061.USD","KURE","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488353","title":"港股醫藥實力抗跌！CXO再扛旗，核心ETF（159137）逆市收紅，金斯瑞創5年新高！兩個問題引發關注……","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488353","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669488353?lang=zh_tw&edition=fundamental","pubTime":"2026-09-23 19:17","pubTimestamp":1790162220,"startTime":"0","endTime":"0","summary":"AI制药产业链上游CXO全天强势，百奥赛图-B领涨近5%，金斯瑞生物科技再涨3.21%创5年新高！港股通医疗ETF华宝标的指数AI制药含量近70%，盘中冲高1.4%，收涨0.1%。图：港股通创新药ETF华宝近6月走势近期港股创新药链相对强势，回顾行情结构，两个问题引发关注：其一，AI制药热度走高，为什么CXO涨势更优。港股通创新药ETF华宝：标的指数100%布局创新药研发类公司，7成仓位押注创新药研发龙头。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-23/doc-inisvivx8562452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FDN","159718","159137","CXO","BK4588","BK4585","BK4550","KURE","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669635154","title":"招商基金李佳存：看好CXO板塊beta機會及創新藥優質個股估值修復行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2669635154","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669635154?lang=zh_tw&edition=fundamental","pubTime":"2026-09-21 17:36","pubTimestamp":1789983360,"startTime":"0","endTime":"0","summary":"行业景气度持续升温，2026年一季度全球AI制药融资18亿美元，接近2025年全年一半。实际影响有限，头部CXO美国客户并未大规模撤退，海外订单未断流，核心原因是中国CXO的质量与成本优势已深度嵌入全球供应链，短期或难以替代。板块表现上，2026年国证CXO指数年内上涨约42%，创新药指数基本持平，两者基本面景气度均向上，看好CXO板块的beta机会及创新药的优质个股估值修复行情。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjsy/2026-09-21/doc-inisqrkc9295042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["REVS","WX","159992","NIFE","BK1161","BK1574","LCO","IBBQ","CXO","LNGR","MEDX","CZA","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"醫藥外包概念盤初走高 昭衍新藥（06127）漲6.14% 機構指CXO為醫藥行業中最亮眼板塊之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669139506?lang=zh_tw&edition=fundamental","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","159938","BK1141","LU0561508036.HKD","LU1242518857.USD","09939","03759","BK1515","BK1589","LU0516422366.SGD","LU1880383366.USD","BK1610","LU0516423091.SGD","LU0456846285.SGD","CXO","HK0000320223.HKD","LU0043850808.USD","03347","02359","LU0051755006.USD","LU0359201612.USD","LU0588546209.SGD","603127","01548","06127","LU0029874905.USD","BK1583","LU0348825331.USD","KURE","LU0516422952.EUR","LU0181495838.USD","LU3063872942.SGD","SG9999002463.SGD","BK1161","LU1794554557.SGD","WX","LU0052750758.USD","LU0307460666.USD","HK0000306701.USD","LU0516422440.USD","01873","LU0348766576.USD","LU0039217434.USD","LU0359202008.SGD","LU2125910500.SGD","LU0029874061.USD","LU0320764599.SGD","LU0540923850.HKD","LU2242644610.SGD","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板塊上揚 昭衍新藥（06127）漲5.64%、金斯瑞生物科技（01548）漲4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668919819?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128522744.USD","06821","LU1251922891.USD","LU0181495838.USD","06127","BK1521","LU0320764243.SGD","02359","LU0516423174.USD","LU2039709279.SGD","CXO","LU0348827113.USD","BK1610","LU0052750758.USD","LU0320764599.SGD","BK1161","LU0856984785.SGD","LU0588546209.SGD","LU0039217434.USD","06160","LU1242518931.SGD","03347","BK0216","LU1719994722.HKD","BK1588","603127","WX","LU1880383366.USD","LU0469268626.HKD","LU0029874905.USD","LU0051755006.USD","LU3063872942.SGD","LU1688375341.USD","01548","LU1242518857.USD","LU2242644610.SGD","LU0561508036.HKD","LU0348825331.USD","LU0029874061.USD","KURE","LU0348735423.USD","LU0634319403.HKD","SG9999002562.SGD","LU0359202008.SGD","IE00B0JY6N72.USD","LU0456846285.SGD","01873","LU0828237510.HKD","02269","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930626","title":"港股異動 | CRO概念股漲幅居前 AIDD利好催化密集 CXO板塊景氣度明確上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668930626?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 10:08","pubTimestamp":1789610899,"startTime":"0","endTime":"0","summary":"消息面上，近期，AIDD利好催化密集。招商证券近期研报指出，CXO板块景气度明确上行。今年上半年国内CXO板块营收、归母净利润同比分别增长24.5%、52.7%，利润增速接近上一轮周期高点；在手订单与新签订单全面回暖，龙头上调全年指引。此外，AI制药有望重塑医药研发业态，提升药物研发效率，板块亦将受益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01873","HK0000306701.USD","02315","HK0000306685.HKD","01548","BK1583","HK0000320223.HKD","BK1191","BK1141","KCAI","BK1576","BK4585","BK4588","06821","CXO","WX","HK0000320264.USD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667218626","title":"生物製品及CXO行業集體與投資者互動 企業「出海」進階 從產品輸出邁向能力輸出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667218626","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667218626?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 00:16","pubTimestamp":1789488960,"startTime":"0","endTime":"0","summary":"9月15日，科创板细分行业集体业绩说明会之生物制品及CXO（医药外包服务）行业集体业绩说明会召开，多家上市公司高管出席。从投资者互动的情况中可知，对于生物制品及CXO行业上市公司，关注的主要事项集中在“出海”、研发等方面。在互动过程中，相关公司高管进行了详细解答。在相关上市公司的半年报和互动过程中，“加大海外市场拓展力度”等信息被频繁提及。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875135164.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163875135164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667685646","title":"ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比","url":"https://stock-news.laohu8.com/highlight/detail?id=2667685646","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667685646?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:02","pubTimestamp":1789383720,"startTime":"0","endTime":"0","summary":"形成赛道级利好共振，重塑市场对创新药研发进度与商业化价值的预期，修复创新药β行情，抬升CXO产业链订单与研发景气度预期。前期创新药、CXO板块经历持续回调，整体估值与市场情绪充分降温，板块点位回落至6-8月宽幅震荡箱体下沿位置，具备一定的技术性反弹空间。展望后市，短期看，在A股整体市场动能偏弱、热点轮动加快、反弹逐步收敛的环境下，前期调整的创新药、CXO板块拥有一定性价比。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuw4057482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02827","IBBQ","BK4585","399300","MEDX","CXO","83130","159992","07233","159982","BK4588","WX","06978","03130","BK1147","BK1574","02846","LNGR","83188","03188","BK1161","FDN","BK4550","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667165628","title":"中信建投：內外需改善逐步傳導訂單與業績 CXO有望進入新一輪增長階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2667165628","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667165628?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:50","pubTimestamp":1789372227,"startTime":"0","endTime":"0","summary":"随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","601066","WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666917512","title":"【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666917512","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666917512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:07","pubTimestamp":1789088866,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年上半年，CXO板块及生命科学上游板块整体业绩表现稳健，行业进入复苏阶段。上半年海外投融资景气度持续，美联储加息预期走弱，早研板块整体的景气度持续走强，AIDD的快速发展也将进一步催化未来相关实验和验证需求的爆发，该机构认为CRO板块有望量价齐升。CDMO板块上半年龙头业绩表现稳健，整体订单增速持续加快，行业景气度回升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06030","LU0417516902.SGD","02367","BK1500","LU2495084118.USD","01530","LU0348827113.USD","LU1146622755.USD","BK0196","LU0463099449.HKD","CXO","KCE","WX","BK1521","LU2328871848.SGD","IE00B3M56506.USD","03933","LU0348783233.USD","SG9999004311.SGD","09688","600030","LU1997245177.USD","LU0244354667.USD","LU1969619763.USD","BK0188","06160","BK1100","LU0561508036.HKD","02268","SG9999014674.SGD","LU0405327494.USD","LU2778985437.USD","06821","09926","LU1997244956.HKD","BK0028","01099","LU0540923850.HKD","BK1574","LU1794554557.SGD","KURE","02196","BK1593","LU1720050803.USD","LU0634319403.HKD","02228","LU2476274308.USD","01789","LU1188198961.HKD","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"東北證券：創新藥BD和商業化持續兑現 CXO超預期，傳統板塊築底拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666513175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","CXO","IBBQ","LNGR","WX","000686","BK0188","MEDX","BK0028","BK0276","BK1161","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665934734","title":"分拆上市成利好？金斯瑞大反攻，飆升逾12%！華寶基金港股通醫療ETF（159137）標的指數漲近2%，CXO全線提振","url":"https://stock-news.laohu8.com/highlight/detail?id=2665934734","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665934734?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 14:06","pubTimestamp":1788847560,"startTime":"0","endTime":"0","summary":"CXO概念集体走强，金斯瑞生物科技飙升逾12%，百奥赛图-B涨超9%，泰格医药、凯莱英涨超7%，药明合联涨超4%。港股通医疗ETF华宝标的指数CXO含量超50%，午后涨近2%！全链布局创新药，关注两大T+0交易利器：港股通医疗ETF华宝：被动跟踪港股通医疗主题指数，重仓创新药产业链，50%CXO+20%创新药，其中药明系占比超38%。港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-08/doc-inirayqy9498188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","FLHK","159137","SPIT","CSD","159828","CXO","ACTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319763","title":"昊海生科：關於參加科創板2026年半年度生物製品及CXO行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319763","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319763?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，昊海生科发布公告称，公司计划于2026年9月15日15：00-17：00参加由上海证券交易所主办的科创板2026年半年度生物制品及CXO行业集体业绩说明会。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX","KSTR","BK0251","BK0239","688366"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"創新藥三大指數上漲、ETF吸金，CXO及科研服務呈高景氣度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665369630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","159992","BK4588","LNGR","06978","WX","BK1161","BK4550","FDN","IBBQ","CXO","BK1574","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":64,"code":"91000000","status":"200"}]}}